Background: Ustekinumab is a human monoclonal antibody that binds to the shared P40 subunit of interleukin (IL)-12 and IL-23 and is approved for the treatment of moderate-to-severe psoriasis. Latent tuberculosis (LTBI) was diagnosed based on a positive tuberculin skin test (TST) or QuantiFERON-TB test without evidence of active tuberculosis (TB). Aim: To evaluate the risk of active tuberculosis reinfection in patients with a history of psoriasis and LTBI after INH prophylaxis treated with Ustekinumab. Case Report: We are describing 3 patients with a history of moderate-to-severe plaque psoriasis and newly identified LTBI who have been treated with INH monotherapy before starting Ustekinumab therapy followed-up over 2 years for any sign of tuberculosis reinfection. Conclusion: Ustekinumab is an option for treating psoriasis and LTBI with minimal risk of reactivation after INH prophylaxis.
References
[1]
Krueger, G., Koo, J., Lebwohl, M., Menter, A., Stern, R.S. and Rolstad, T. (2001) The Impact of Psoriasis on Quality of Life: Results of a 1998 National Psoriasis Foundation Patient-Membership Survey. Archives of Dermatology, 137, 280-284.
[2]
Schön, M.P. and Boehncke, W.-H. (2005) Psoriasis. New England Journal of Medicine, 352, 1899-1912. https://doi.org/10.1056/NEJMra041320
[3]
Menter, A., Strober, B.E., Kaplan, D.H., Kivelevitch, D., Prater, E.F., Stoff, B., et al. (2019) Joint AAD-NPF Guidelines of Care for the Management and Treatment of Psoriasis with Biologics. Journal of the American Academy of Dermatology, 80, 1029-1072. https://doi.org/10.1016/j.jaad.2018.11.057
[4]
Tsai, T.F., Ho, V., Song M., Szapary, P., Kato, T., Wasfi, Y., et al. (2012) The Safety of Ustekinumab Treatment in Patients with Moderate-to-Severe Psoriasis and Latent Tuberculosis Infection. British Journal of Dermatology, 167, 1145-1152. https://doi.org/10.1111/j.1365-2133.2012.11142.x
[5]
World Health Organization (2011) Global Tuberculosis Control 2011. https://www.who.int/publications-detail-redirect/9789241564380
[6]
World Health Organization Media Centre (2012, March) Tuberculosis Fact Sheet No. 104. https://www.who.int/news-room/fact-sheets/detail/tuberculosis
[7]
Wallis, R.S., Pai, M., Menzies, D., Doherty, T.M., Walzl, G., Perkins, M.D., et al. (2010) Biomarkers and Diagnostics for Tuberculosis: Progress, Needs, and Translation into Practice. Lancet, 375, 1920-19237. https://doi.org/10.1016/S0140-6736(10)60359-5
[8]
World Health Organization Regional Office for Southeast Asia, Communicable Diseases Department (2012) Tuberculosis. TB/HIV. http://www.searo.who.int/en/section10/section2097/section2129.htm
[9]
Doherty, S.D., van Voorhees, A., Lebwohl, M.G., Korman, N.J., Young, M.S. and Hsu, S. (2008) National Psoriasis Foundation Consensus Statement on Screening for Latent Tuberculosis Infection in Patients with Psoriasis Treated with Systemic and Biologic Agents. Journal of the American Academy of Dermatology, 59, 209-217. https://doi.org/10.1016/j.jaad.2008.03.023
[10]
Flynn, J.L. and Chan, J. (2001) Immunology of Tuberculosis. Annual Review of Immunology, 19, 93-129. https://doi.org/10.1146/annurev.immunol.19.1.93
[11]
Germann, T. and Rude, E. (1995) Interleukin-12. International Archives of Allergy and Immunology, 108, 103-112. https://doi.org/10.1159/000237126
[12]
D’Elios, M.M., Del Prete, G. and Amedei, A. (2010) Targeting IL-23 in Human Diseases. Expert Opinion on Therapeutic Targets, 14, 759-774. https://doi.org/10.1517/14728222.2010.497143
[13]
O’Quinn, D.B., Palmer, M.T., Lee, Y.K. and Weaver, C.T. (2008) Chapter 5 Emergence of the Th17 Pathway and Its Role in Host Defense. Advances in Immunology, 99, 115-163. https://doi.org/10.1016/S0065-2776(08)00605-6
[14]
Centers for Disease Control and Prevention (2000) Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection. Morbidity and Mortality Weekly Report, 49, 1-51.
[15]
Chiu, H.Y., Hsueh, P.R. and Tsai, T.F. (2011) Clinical Experience of QuantiFER-ON-TB Gold Testing in Patients with Psoriasis Treated with Tumor Necrosis Factor Blockers in Taiwan. British Journal of Dermatology, 164, 553-559. https://doi.org/10.1111/j.1365-2133.2010.10137.x
[16]
Hsiao, C.-Y., Chiu, H.-Y., Wang, T.-S. and Tsai, T.-F. (2017) Serial QuantiFERON-TB Gold Testing in Patients with Psoriasis Treated with Ustekinumab. PLoS ONE, 12, Article ID: e0184178. https://doi.org/10.1371/journal.pone.0184178
